Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05617313 |
|
Recruitment Status :
Suspended
(Interim Analysis)
First Posted : November 15, 2022
Last Update Posted : March 4, 2024
|
Sponsor:
Jeffrey Clarke
Collaborators:
Merck Sharp & Dohme LLC
Grid Therapeutics
Information provided by (Responsible Party):
Jeffrey Clarke, Duke University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Suspended |
|---|---|
| Estimated Primary Completion Date : | January 2029 |
| Estimated Study Completion Date : | January 2030 |